BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 865 filers reported holding BAXTER INTL INC in Q3 2015. The put-call ratio across all filers is 0.26 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $385,000 | +84.2% | 4,488 | +72.6% | 0.00% | +50.0% |
| Q3 2021 | $209,000 | +21.5% | 2,600 | +21.8% | 0.00% | +100.0% |
| Q2 2021 | $172,000 | -8.5% | 2,134 | -4.4% | 0.00% | 0.0% |
| Q1 2021 | $188,000 | -9.6% | 2,232 | -14.0% | 0.00% | -50.0% |
| Q4 2020 | $208,000 | -66.0% | 2,595 | -65.9% | 0.00% | -66.7% |
| Q3 2020 | $612,000 | -56.6% | 7,607 | -53.6% | 0.01% | -60.0% |
| Q2 2020 | $1,411,000 | -16.8% | 16,386 | -21.5% | 0.02% | -28.6% |
| Q1 2020 | $1,695,000 | -88.1% | 20,879 | -89.8% | 0.02% | -86.4% |
| Q2 2015 | $14,231,000 | +8.6% | 203,900 | +6.6% | 0.15% | +8.5% |
| Q1 2015 | $13,101,000 | -38.6% | 191,300 | -34.3% | 0.14% | -37.7% |
| Q4 2014 | $21,325,000 | -2.1% | 291,300 | -3.9% | 0.23% | +0.4% |
| Q3 2014 | $21,791,000 | -0.6% | 303,100 | 0.0% | 0.23% | +5.6% |
| Q2 2014 | $21,923,000 | -1.7% | 303,100 | 0.0% | 0.22% | -5.3% |
| Q1 2014 | $22,304,000 | +0.5% | 303,100 | -5.0% | 0.23% | 0.0% |
| Q4 2013 | $22,202,000 | +180.4% | 318,900 | +164.0% | 0.23% | +155.1% |
| Q3 2013 | $7,917,000 | – | 120,800 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |